
    
      This study is a Phase1, randomized, double-blind, placebo-controlled, single dose, dose
      escalation safety and tolerability study of NPT189 in health subjects. Six dose cohorts are
      planned each with a maximum of 8 participants per cohort. Participants will receive NPT189 by
      intravenous (IV) or a matching placebo by intravenous infusion. Safety, tolerability, and
      pharmacokinetics will be assessed.
    
  